Protox plans clinical trial of PRX302 in enlarged prostate

By Lisa Kerner

Charlotte, N.C., Sept. 21 - Protox Therapeutics Inc. submitted a Clinical Trial Application to Health Canada for PRX302, its lead candidate in the PORxin technology platform.

The Vancouver, B.C., pharmaceutical company plans a phase 1 clinical trial of PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate), a $4 billion market.

PRX302 reduced prostate size by destroying tissue in the presence of prostate specific antigen in preclinical studies.

"With this filing we continue to advance PRX302 by taking full advantage of the dramatic reduction in prostate size shown in preclinical studies," president and chief executive officer Fahar Merchant said in a company news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.